Chemoenzymatic synthesis of 2,6-disubstituted tetrahydropyrans with high σ1 receptor affinity, antitumor and analgesic activity

被引:11
作者
Kopp, Nicole [1 ]
Civenni, Gianluca [2 ]
Marson, Domenico [3 ]
Laurini, Erik [3 ]
Pricl, Sabrina [3 ,4 ]
Catapano, Carlo, V [2 ]
Humpf, Hans-Ulrich [5 ]
Almansa, Carmen [6 ]
Nieto, Francisco Rafael [7 ,8 ]
Schepmann, Dirk [1 ]
Wuensch, Bernhard [1 ,9 ]
机构
[1] Westfalische Wilhelms Univ Munster, Inst Pharmazeut & Med Chem, Corrensstr 48, D-48149 Munster, Germany
[2] Univ Svizzera Italiana USI, Inst Oncol Res, Via Vincenzo Vela 6, CH-6500 Bellinzona, Switzerland
[3] Univ Trieste, Mol Biol & Nanotechnol Lab MoIBNL UniTS, DEA, I-34127 Trieste, Italy
[4] Univ Lodz, Fac Biol & Environm Protect, Dept Gen Biophys, Lodz, Poland
[5] Westfcil Wilhelms Univ Munster, Inst Lebensmittelchem, Corrensstr 45, D-48149 Munster, Germany
[6] Esteve Pharmaceut SA, Baldiri Reixach 4-8, Barcelona 08028, Spain
[7] Univ Granada, Dept Pharmacol & Neurosci Inst, Biomed Res Ctr, Granada 18010, Spain
[8] Biosanitary Res Inst, Granada 18010, Spain
[9] Westfalische Wilhelms Univ Munster, Chem Biol Ion Channels Chemb, D-2515 Munster, Germany
关键词
sigma(1) receptor; 2,6-Disubstituted tetrahydropyrans; Chemoenzymatic synthesis; Stereochemistry; Kinetic resolution; Chiral HPLC; CD spectroscopy; sigma(1) receptor affinity; Selectivity; Structure affinity relationships; Docking studies; Molecular dynamics; Steered molecular dynamics; Antitumor activity; Androgen negative human prostate cancer cell line DU145; Neuropathic pain; Analgesic activity; Antiallodynic activity; CHIRAL BUILDING-BLOCKS; MOLECULAR-DYNAMICS; RECOGNITION SITES; LIGAND-BINDING; CLONING; IDENTIFICATION; PHARMACOLOGY; ANTAGONIST; RESOLUTION; EXPRESSION;
D O I
10.1016/j.ejmech.2021.113443
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
1,3-Dioxanes 1 and cyclohexanes 2 bearing a phenyl ring and an aminoethyl moiety in 1,3-relationship to each other represent highly potent sigma(1) receptor antagonists. In order to increase the chemical stability of the acetalic 1,3-dioxanes 1 and the polarity of the cyclohexanes 2, tetrahydropyran derivatives 3 equipped with the same substituents were designed, synthesized and pharmacologically evaluated. The key step of the synthesis was a lipase-catalyzed enantioselective acetylation of the alcohol (R)-5 leading finally to enantiomerically pure test compounds 3a-g. With respect to sigma(1) receptor affinity and selectivity over a broad range of related (sigma(2), PCP binding site) and further targets, the enantiomeric benzylamines 3a and cyclohexylmethylamines 3b represent the most promising drug candidates of this series. However, the eudismic ratio for s1 binding is only in the range of 2.5-e3.3. Classical molecular dynamics (MD) simulations confirmed the same binding pose for both the tetrahydropyran 3 and cyclohexane derivatives 2 at the sigma(1) receptor, according to which: i) the protonated amino moiety of (2S,6R)-3a engages the same key polar interactions with Glu172 (ionic) and Phe107 (pi-cation), ii) the lipophilic parts of (2S,6R)-3a are hosted in three hydrophobic regions of the sigma(1) receptor, and iii) the O-atom of the tetrahydropyran derivatives 3 does not show a relevant interaction with the sigma(1) receptor. Further in silico evidences obtained by the application of free energy perturbation and steered MD techniques fully supported the experimentally observed difference in receptor/ligand affinities. Tetrahydropyrans 3 require a lower dissociative force peak than cyclohexane analogs 2. Enantiomeric benzylamines 3a and cyclohexylmethylamines 3b were able to inhibit the growth of the androgen negative human prostate cancer cell line DU145. The cyclohexylmethylamine (2S,6R)-3b showed the highest sigma(1) affinity (K-i(sigma(1)) = 0.95 nM) and the highest analgesic activity in vivo (67%). (C) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:17
相关论文
共 75 条
[1]   Identification of the gene that codes for the σ2 receptor [J].
Alon, Assaf ;
Schmidt, Hayden R. ;
Wood, Michael D. ;
Sahn, James J. ;
Martin, Stephen F. ;
Kruse, Andrew C. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (27) :7160-7165
[2]   Sigma receptors and cancer: Possible involvement of ion channels [J].
Aydar, E ;
Palmer, CP ;
Djamgoz, MBA .
CANCER RESEARCH, 2004, 64 (15) :5029-5035
[3]   Human surrogate models of neuropathic pain: validity and limitations [J].
Binder, Andreas .
PAIN, 2016, 157 (02) :S48-S52
[4]   Enantioselective Henry Addition of Methyl 4-Nitrobutyrate to Aldehydes. Chiral Building Blocks for 2-Pyrrolidinones and Other Derivatives [J].
Blay, Gonzalo ;
Hernandez-Olmos, Victor ;
Pedro, Jose R. .
ORGANIC LETTERS, 2010, 12 (13) :3058-3061
[5]   Sigma-1 Receptor Inhibition Reduces Neuropathic Pain Induced by Partial Sciatic Nerve Transection in Mice by Opioid-Dependent and - Independent Mechanisms [J].
Bravo-Caparros, Inmaculada ;
Perazzoli, Gloria ;
Yeste, Sandra ;
Cikes, Domagoj ;
Manuel Baeyens, Jose ;
Jose Cobos, Enrique ;
Rafael Nieto, Francisco .
FRONTIERS IN PHARMACOLOGY, 2019, 10
[6]   Design, (Radio)Synthesis, and in Vitro and in Vivo Evaluation of Highly Selective and Potent Matrix Metalloproteinase 12 (MMP-12) Inhibitors as Radiotracers for Positron Emission Tomography [J].
Butsch, Viktoria ;
Boergel, Frederik ;
Galla, Fabian ;
Schwegmann, Katrin ;
Hermann, Sven ;
Schaefers, Michael ;
Riemann, Burkhard ;
Wuensch, Bernhard ;
Wagner, Stefan .
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (09) :4115-4134
[7]  
Case D. A., 2019, AMBER 2019
[8]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[9]   Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands [J].
Cobos, E. J. ;
Entrena, J. M. ;
Nieto, F. R. ;
Cendan, C. M. ;
Del Pozo, E. .
CURRENT NEUROPHARMACOLOGY, 2008, 6 (04) :344-366
[10]  
Collier TL, 2007, CURR PHARM DESIGN, V13, P51